Full Year 2007 Results Date Notification - 21 Feb...(com/shire/20080221 target _new http://g...)
Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
Full Year 2007 Results Date Notification - 21 February 2008
Date:2/12/2008
com/shire/20080221" target="_new">http://gaia.world-television.com/shire/20080221
* Email verification is required
Notes to Editors
Shire plc Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company's website: http://www.shire.com.
'/>"/>
| SOURCE Shire plc Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
4. CNS Response Announces Fiscal Third Quarter 2007 Results
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Martek to Announce Third Quarter 2007 Results on September 5, 2007
Post Your Comments:
Breaking Biology Technology:EUCODIS Bioscience Appoints Thomas Fischer as New CEO 2AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 3Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 2Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 3WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening 2
[0] EUCODIS Bioscience Appoints Thomas Fischer as New CEO[0] AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia[0] Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. [0] WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening
Other Biology Technology:Boston Scientific Announces FDA Approval of TAXUS(R) Express2(TM) Atom(TM) Stent System, First Drug-Eluting Stent For Small Vessels 2Boston Scientific Announces FDA Approval of TAXUS(R) Express2(TM) Atom(TM) Stent System, First Drug-Eluting Stent For Small Vessels 3Boston Scientific Announces FDA Approval of TAXUS(R) Express2(TM) Atom(TM) Stent System, First Drug-Eluting Stent For Small Vessels 43SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAO 23SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAO 3TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds 2TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds 3TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds 4
Boston Scientific Announces FDA Approval of TAXUS(R) Express2(TM) Atom(TM) Stent System, First Drug-Eluting Stent For Small Vessels3SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAOTorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds
Breaking Biology News(10 mins):Springer signs co-publishing agreement with the Royal Swedish Academy of Sciences 2Improving the odds 2The Academy of Natural Sciences and Temple Press revive rare natural history work in new book 2EPA grant to University of Chicago for research on food allergy triggers 9332 1Scientists discover gene mutation responsible for hereditary neuroendocrine tumor 9330 1Scientists discover gene mutation responsible for hereditary neuroendocrine tumor 9330 2Scientists discover gene mutation responsible for hereditary neuroendocrine tumor 9330 3Spring cold snap helps with stream ecosystem research 9328 1Spring cold snap helps with stream ecosystem research 9328 2
Other Biology News:Understanding the functions of diversity 2Scientists discover a molecular scaffold that guides connections between brain cells 2Scientists discover a molecular scaffold that guides connections between brain cells 3Study identifies trends of vitamin B6 status in US population sample 2Study identifies trends of vitamin B6 status in US population sample 3
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |